CPhI Announces Members for Expert Industry Panel - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI Announces Members for Expert Industry Panel


CPhI Worldwide established an expert industry panel that will leverage its members' collective expertise to create monthly and annual reports exploring changes in the pharmaceutical industry. The founding panel members are: Ali Afnan, president at Step Change Pharma; Brian Carlin, director of Open Innovation at FMC; Bikash Chatterjee, president and CTO at Pharmatech Associates; Girish Malhotra, president and founder of Epcot International; Hedley Rees, managing director at PharmaFlow; and Ajaz Hussain, CSO and president of Biotechnology at Wockhardt, CPhI announced in a June 3, 2013 press release.

Each panel member was chosen following an exhaustive selection process involving industry peers and journalists to ensure that the panel has the appropriate expertise to independently and holistically examine global trends. In total, CPhI envisages harnessing the collective knowledge of between 12 and 15 experts, covering the entire pharmaceutical supply chain from R&D through to finished products. Additional members are expected to join the panel soon. The members of the panel will collaborate and draw upon their combined expertise to provide foresights into the global pharmaceutical industry. The panel’s first report on formulation and ingredients is planned for publication in June. The panel will scrutinize how the industry will change in the coming decade in an annual report to be produced prior to the CPhI event in October.

The founding members include leading experts on APIs and excipients (Girish Malhorta and Brian Carlin respectively) and regulatory experts (Ajaz Hussain and Ali Afnan). The panel will leverage the knowledge of Hedley Rees on supply-chain issues and the experience of Bikash Chatterjee on quality systems and the Asian market.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here